ClinicalTrials.gg
CompletedNCT04881461RhapsodyUpdated Dec 16, 2024Results posted

A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis

A Phase 3 interventional study of 5-grass mix SLIT-drops and Placebo in Allergy, sponsored by ALK-Abelló A/S. Completed at 48 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by ALK-Abelló A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
445
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 30 studies in Hypersensitivity by ALK-Abelló A/S — none open to participants now, none under way, none of them phase 3. Hypersensitivity · ALK-Abelló A/S.

Enrollment
6th of 25
445 · median 226
Started
2021
with 1 other
Phase 3
13 of 30
none open now
Registered
28th of 30
by date

Among the 30 studies in Hypersensitivity by ALK-Abelló A/S, this one is the 6th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2021, is one of 13 in phase 3, and was the 28th registered.

Hypersensitivity

1,058 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.

Browse Hypersensitivity studies →

Open to participants now

None of the 30 studies in Hypersensitivity by ALK-Abelló A/S is open now. The open studies under Hypersensitivity, anywhere →

Who these studies take

Of the 101 Hypersensitivity studies recruiting now, 37 (37%) set no upper age limit and 52 (51%) stop at 75 or younger; 56 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies in Hypersensitivity by ALK-Abelló A/S as a file.
02

Study summary

This is a 2 year clinical study to compare 5-grass mix SLIT-drops with placebo in relieving grass pollen-induced rhinoconjunctivitis symptoms and in use of symptom-relieving medication during the second grass pollen season (peak grass pollen season, PGPS)

The study will collect health-related quality of life data in the groups treated with 5-grass mix SLIT-drops or with placebo during the first and second PGPS.

The trial medication used is already approved to treat allergic rhinitis caused by grass pollen in adults in several countries.

Read the detailed description

This trial is a 2 year, parallel-group, double-blind, placebo-controlled phase III trial to evaluate efficacy and safety of the 5-grass mix SLIT-drops in adults with grass pollen-induced rhinoconjunctivitis with or without asthma. Approximately 440 adults will be enrolled in the trial and will receive the 5-grass mix SLIT-drops or placebo. The trial is conducted in several European countries.

03

Conditions studied

  • Allergy

Browse trials for

Keywords

  • Allergic rhinoconjunctivitis
  • Adults
  • Grass
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged ≥18 years on the day is obtained
  2. A clinical history of grass pollen-induced allergic rhinoconjunctivitis for two years or more with or without asthma
  3. A clinical history of severe allergic rhinoconjunctivitis symptoms (interfering with usual daily activities or sleep) induced by grass pollen, which remain troublesome despite symptomatic treatment with antihistamines, nasal or eye drops during the previous grass pollen season
  4. Positive specific immunoglobulin E (IgE) (defined as ≥class 2, ≥0.70 kU/l) against grass: Phleum pratense
  5. Positive skin prick test to Phleum pratense at screening

Exclusion criteria

Exclusion Criteria:

  1. Has a history of symptomatic seasonal and/or perennial allergic rhinoconjunctivitis and/or asthma caused by an allergen other than grass pollen, to which the subject is exposed, which could potentially overlap with the efficacy assessment periods
  2. Within the last 3 months before the randomisation visit, has had an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalisation, or treatment with systemic
  3. SLIT treatment with any grass pollen AIT for more than 1 month within the last 5 years. In addition, any SLIT treatment with grass pollen AIT within the previous 12 months
  4. SCIT treatment with any grass AIT reaching the maintenance dose within the last 5 years. In addition, any SCIT treatment with grass AIT within the previous 12 months
  5. Ongoing treatment with any allergy immunotherapy product
  6. Uncontrolled or severe asthma requiring daily use of more than 800 mcg budesonide or equivalent at screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
445 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Glycerol, carbonate, sodium chloride One single-dose container (0.5 ml) once daily

    Drug: Placebo

  • Experimental
    5-grass mix SLIT-drops

    Grass mix sublingual allergy immunotherapy drops One single-dose container (0.5 ml) once daily. 50 SRU/day for five consecutive days followed by 150 SRU/day for five additional consecutive days. Maintenance: 300 SRU/day from day 11.

    Drug: 5-grass mix SLIT-drops

Interventions

  • Drug5-grass mix SLIT-drops

    Sublingual allergy immunotherapy drops, for daily administration

    Also known as: SLIToneULTRA

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Peak Grass Pollen Season (PGPS)

    The average daily TCS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms and in use of symptom-relieving medication (on a scale from 0 to 38). Higher scores indicate more severe symptoms and/or more medication use. The endpoint is calculated as the average score of all reported daily values during the 2nd PGPS.

    Time frame: During the 2nd PGPS (14 days)

Secondary outcomes

  1. Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 2nd Peak Grass Pollen Season (PGPS)

    The RQLQ measures the rhinoconjunctivitis quality of life. The RQLQ contains 28 questions, each scored on a 7-point scale (0 = not impaired at all; 6 = severely impaired). The overall RQLQ score is a mean of the 28 questions. Higher scores indicate worse quality of life. The endpoint is calculated as the average score of all reported weekly values during the 2nd PGPS.

    Time frame: During the 2nd PGPS (14 days)

  2. Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 1st Peak Grass Pollen Season (PGPS)

    The average daily TCS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms and in use of symptom-relieving medication (on a scale from 0 to 38). Higher scores indicate more severe symptoms and/or more medication use. The endpoint is calculated as the average score of all reported daily values during the 1st PGPS.

    Time frame: During the 1st PGPS (14 days)

  3. Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 1st Peak Grass Pollen Season (PGPS)

    The RQLQ measures the rhinoconjunctivitis quality of life. The RQLQ contains 28 questions, each scored on a 7-point scale (0 = not impaired at all; 6 = severely impaired). The overall RQLQ score is a mean of the 28 questions. Higher scores indicate worse quality of life. The endpoint is calculated as the average score of all reported weekly values during the 1st PGPS.

    Time frame: During the 1st PGPS (14 days)

  4. Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 1st Entire Grass Pollen Season (EGPS)

    The RQLQ measures the rhinoconjunctivitis quality of life. The RQLQ contains 28 questions, each scored on a 7-point scale (0 = not impaired at all; 6 = severely impaired). The overall RQLQ score is a mean of the 28 questions. Higher scores indicate worse quality of life. The endpoint is calculated as the average score of all reported weekly values during the 1st EGPS.

    Time frame: During the 1st EGPS (observed mean duration of approximately 8 weeks)

  5. Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 2nd Entire Grass Pollen Season (EGPS)

    The RQLQ measures the rhinoconjunctivitis quality of life. The RQLQ contains 28 questions, each scored on a 7-point scale (0 = not impaired at all; 6 = severely impaired). The overall RQLQ score is a mean of the 28 questions. Higher scores indicate worse quality of life. The endpoint is calculated as the average score of all reported weekly values during the 2nd EGPS.

    Time frame: During the 2nd EGPS (observed mean duration of approximately 9 weeks)

  6. Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 1st Entire Grass Pollen Season (EGPS)

    The average daily TCS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms and in use of symptom-relieving medication (on a scale from 0 to 38). Higher scores indicate more severe symptoms and/or more medication use. The endpoint is calculated as the average score of all reported daily values during the 1st EGPS.

    Time frame: During the 1st EGPS (observed mean duration of approximately 8 weeks)

  7. Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Entire Grass Pollen Season (EGPS)

    The average daily TCS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms and in use of symptom-relieving medication (on a scale from 0 to 38). Higher scores indicate more severe symptoms and/or more medication use. The endpoint is calculated as the average score of all reported daily values during the 2nd EGPS.

    Time frame: During the 2nd EGPS (observed mean duration of approximately 9 weeks)

  8. Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 1st Peak Grass Pollen Season (PGPS)

    The average DSS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms (on a scale from 0 to18). Higher scores indicate more severe symptoms. The endpoint is calculated as the average score of all reported daily values during the 1st PGPS.

    Time frame: During the 1st PGPS (14 days)

  9. Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 2nd Peak Grass Pollen Season (PGPS)

    The average DSS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms (on a scale from 0 to18). Higher scores indicate more severe symptoms. The endpoint is calculated as the average score of all reported daily values during the 2nd PGPS.

    Time frame: During the 2nd PGPS (14 days)

  10. Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 1st Entire Grass Pollen Season (EGPS)

    The average DSS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms (on a scale from 0 to18). Higher scores indicate more severe symptoms. The endpoint is calculated as the average score of all reported daily values during the 1st EGPS.

    Time frame: During the 1st EGPS (observed mean duration of approximately 8 weeks)

  11. Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 2nd Entire Grass Pollen Season (EGPS)

    The average DSS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms (on a scale from 0 to18). Higher scores indicate more severe symptoms. The endpoint is calculated as the average score of all reported daily values during the 2nd EGPS.

    Time frame: During the 2nd EGPS (observed mean duration of approximately 9 weeks)

  12. Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 1st Peak Grass Pollen Season (PGPS)

    The average DMS evaluates the treatment effect based on reduction in daily use of rhinoconjunctivitis symptom-relieving medication (on a scale from 0 to 20). Higher scores indicate more medication use. The endpoint is calculated as the average score of all reported daily values during the 1st PGPS.

    Time frame: During the 1st PGPS (14 days)

  13. Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 2nd Peak Grass Pollen Season (PGPS)

    The average DMS evaluates the treatment effect based on reduction in daily use of rhinoconjunctivitis symptom-relieving medication (on a scale of 0 to 20). Higher scores indicate more medication use. The endpoint is calculated as the average score of all reported daily values during the 2nd PGPS.

    Time frame: During the 2nd PGPS (14 days)

  14. Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 1st Entire Grass Pollen Season (EGPS)

    The average DMS evaluates the treatment effect based on reduction in daily use of rhinoconjunctivitis symptom-relieving medication(on a scale from 0 to 20). Higher scores indicate more medication use. The endpoint is calculated as the average score of all reported daily values during the 1st EGPS.

    Time frame: During the 1st EGPS (observed mean duration of approximately 8 weeks)

  15. Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 2nd Entire Grass Pollen Season (EGPS)

    The average DMS evaluates the treatment effect based on reduction in daily use of rhinoconjunctivitis symptom-relieving medication (on a scale from 0 to 20). Higher scores indicate more medication use. The endpoint is calculated as the average score of all reported daily values during the 2nd EGPS.

    Time frame: During the 2nd EGPS (observed mean duration of approximately 9 weeks)

07

Results

Posted Dec 16, 2024

Participant flow

445 participants were randomized and treated. Participants were recruited from 45 sites in 6 countries (Czechia, Estonia, France, Latvia, Lithuania, and Poland).

Participant flow — Overall Study
MilestonePlacebo5-grass Mix SLIT-drops
Started223222
Completed196193
Not completed2729
Withdrew: Adverse event24
Withdrew: Withdrawal by subject1919
Withdrew: Lost to follow-up44
Withdrew: Lack of efficacy10
Withdrew: Reason stated as "other" in crf12

Outcome measures

PrimaryAverage Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Peak Grass Pollen Season (PGPS)

The average daily TCS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms and in use of symptom-relieving medication (on a scale from 0 to 38). Higher scores indicate more severe symptoms and/or more medication use. The endpoint is calculated as the average score of all reported daily values during the 2nd PGPS.

Time frame:
During the 2nd PGPS (14 days)
Reported as:
Mean · score on a scale
Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Peak Grass Pollen Season (PGPS)
score on a scalePlacebo5-grass Mix SLIT-drops
Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Peak Grass Pollen Season (PGPS)7.10 ± 0.515.22 ± 0.42
Statistical analysis
  • Placebo vs 5-grass Mix SLIT-drops · Mixed Models Analysis · p = 0.0036 (Adjusted P-value.) · Mean difference (final values): 1.88 · 95% CI 0.60 to 3.17Placebo vs 5-grass mix SLIT-drops
SecondaryAverage Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 2nd Peak Grass Pollen Season (PGPS)

The RQLQ measures the rhinoconjunctivitis quality of life. The RQLQ contains 28 questions, each scored on a 7-point scale (0 = not impaired at all; 6 = severely impaired). The overall RQLQ score is a mean of the 28 questions. Higher scores indicate worse quality of life. The endpoint is calculated as the average score of all reported weekly values during the 2nd PGPS.

Time frame:
During the 2nd PGPS (14 days)
Reported as:
Mean · score on a scale
Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 2nd Peak Grass Pollen Season (PGPS)
score on a scalePlacebo5-grass Mix SLIT-drops
Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 2nd Peak Grass Pollen Season (PGPS)1.04 ± 0.080.86 ± 0.08
Statistical analysis
  • Placebo vs 5-grass Mix SLIT-drops · Mixed Models Analysis · p = 0.1111 (Adjusted P-value.) · Mean difference (final values): 0.17 · 95% CI -0.04 to 0.39Placebo vs 5-grass mix SLIT-drops
SecondaryAverage Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 1st Peak Grass Pollen Season (PGPS)

The average daily TCS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms and in use of symptom-relieving medication (on a scale from 0 to 38). Higher scores indicate more severe symptoms and/or more medication use. The endpoint is calculated as the average score of all reported daily values during the 1st PGPS.

Time frame:
During the 1st PGPS (14 days)
Reported as:
Mean · score on a scale
Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 1st Peak Grass Pollen Season (PGPS)
score on a scalePlacebo5-grass Mix SLIT-drops
Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 1st Peak Grass Pollen Season (PGPS)8.10 ± 0.546.76 ± 0.42
Statistical analysis
  • Placebo vs 5-grass Mix SLIT-drops · Mixed Models Analysis · p = 0.0417 (Observed P-value) · Mean difference (final values): 1.33 · 95% CI -0.01 to 2.67Placebo vs 5-grass SLIT-drops
SecondaryAverage Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 1st Peak Grass Pollen Season (PGPS)

The RQLQ measures the rhinoconjunctivitis quality of life. The RQLQ contains 28 questions, each scored on a 7-point scale (0 = not impaired at all; 6 = severely impaired). The overall RQLQ score is a mean of the 28 questions. Higher scores indicate worse quality of life. The endpoint is calculated as the average score of all reported weekly values during the 1st PGPS.

Time frame:
During the 1st PGPS (14 days)
Reported as:
Mean · score on a scale
Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 1st Peak Grass Pollen Season (PGPS)
score on a scalePlacebo5-grass Mix SLIT-drops
Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 1st Peak Grass Pollen Season (PGPS)1.26 ± 0.091.19 ± 0.08
Statistical analysis
  • Placebo vs 5-grass Mix SLIT-drops · Mixed Models Analysis · p = 0.4984 (Observed P-value) · Mean difference (final values): 0.08 · 95% CI -0.15 to 0.30Placebo vs 5-grass SLIT drops
SecondaryAverage Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 1st Entire Grass Pollen Season (EGPS)

The RQLQ measures the rhinoconjunctivitis quality of life. The RQLQ contains 28 questions, each scored on a 7-point scale (0 = not impaired at all; 6 = severely impaired). The overall RQLQ score is a mean of the 28 questions. Higher scores indicate worse quality of life. The endpoint is calculated as the average score of all reported weekly values during the 1st EGPS.

Time frame:
During the 1st EGPS (observed mean duration of approximately 8 weeks)
Reported as:
Mean · score on a scale
Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 1st Entire Grass Pollen Season (EGPS)
score on a scalePlacebo5-grass Mix SLIT-drops
Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 1st Entire Grass Pollen Season (EGPS)1.16 ± 0.091.09 ± 0.08
Statistical analysis
  • Placebo vs 5-grass Mix SLIT-drops · Mixed Models Analysis · p = 0.4438 (Observed P-value) · Mean difference (final values): 0.07 · 95% CI -0.12 to 0.27Placebo vs 5-grass mix SLIT-drops
SecondaryAverage Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 2nd Entire Grass Pollen Season (EGPS)

The RQLQ measures the rhinoconjunctivitis quality of life. The RQLQ contains 28 questions, each scored on a 7-point scale (0 = not impaired at all; 6 = severely impaired). The overall RQLQ score is a mean of the 28 questions. Higher scores indicate worse quality of life. The endpoint is calculated as the average score of all reported weekly values during the 2nd EGPS.

Time frame:
During the 2nd EGPS (observed mean duration of approximately 9 weeks)
Reported as:
Mean · score on a scale
Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 2nd Entire Grass Pollen Season (EGPS)
score on a scalePlacebo5-grass Mix SLIT-drops
Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 2nd Entire Grass Pollen Season (EGPS)1.03 ± 0.080.83 ± 0.07
Statistical analysis
  • Placebo vs 5-grass Mix SLIT-drops · Mixed Models Analysis · p = 0.0363 (Observed P-value.) · Mean difference (final values): 0.20 · 95% CI 0.01 to 0.38Placebo vs 5-grass mix SLIT-drops
SecondaryAverage Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 1st Entire Grass Pollen Season (EGPS)

The average daily TCS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms and in use of symptom-relieving medication (on a scale from 0 to 38). Higher scores indicate more severe symptoms and/or more medication use. The endpoint is calculated as the average score of all reported daily values during the 1st EGPS.

Time frame:
During the 1st EGPS (observed mean duration of approximately 8 weeks)
Reported as:
Mean · score on a scale
Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 1st Entire Grass Pollen Season (EGPS)
score on a scalePlacebo5-grass Mix SLIT-drops
Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 1st Entire Grass Pollen Season (EGPS)7.42 ± 0.546.23 ± 0.45
Statistical analysis
  • Placebo vs 5-grass Mix SLIT-drops · Mixed Models Analysis · p = 0.0329 (Observed P-value.) · Mean difference (final values): 1.19 · 95% CI 0.06 to 2.31Placebo vs 5-grass mix SLIT drops
SecondaryAverage Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Entire Grass Pollen Season (EGPS)

The average daily TCS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms and in use of symptom-relieving medication (on a scale from 0 to 38). Higher scores indicate more severe symptoms and/or more medication use. The endpoint is calculated as the average score of all reported daily values during the 2nd EGPS.

Time frame:
During the 2nd EGPS (observed mean duration of approximately 9 weeks)
Reported as:
Mean · score on a scale
Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Entire Grass Pollen Season (EGPS)
score on a scalePlacebo5-grass Mix SLIT-drops
Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Entire Grass Pollen Season (EGPS)6.58 ± 0.504.86 ± 0.43
Statistical analysis
  • Placebo vs 5-grass Mix SLIT-drops · Mixed Models Analysis · p = 0.0016 (Observed P-value.) · Mean difference (final values): 1.73 · 95% CI 0.66 to 2.79Placebo vs 5-grass mix SLIT-drops
SecondaryAverage Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 1st Peak Grass Pollen Season (PGPS)

The average DSS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms (on a scale from 0 to18). Higher scores indicate more severe symptoms. The endpoint is calculated as the average score of all reported daily values during the 1st PGPS.

Time frame:
During the 1st PGPS (14 days)
Reported as:
Mean · score on a scale
Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 1st Peak Grass Pollen Season (PGPS)
score on a scalePlacebo5-grass Mix SLIT-drops
Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 1st Peak Grass Pollen Season (PGPS)4.08 ± 0.273.83 ± 0.23
Statistical analysis
  • Placebo vs 5-grass Mix SLIT-drops · Mixed Models Analysis · p = 0.4502 (Observed P-value.) · Mean difference (final values): 0.25 · 95% CI -0.42 to 0.92Placebo vs 5-grass mix SLIT-drops
SecondaryAverage Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 2nd Peak Grass Pollen Season (PGPS)

The average DSS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms (on a scale from 0 to18). Higher scores indicate more severe symptoms. The endpoint is calculated as the average score of all reported daily values during the 2nd PGPS.

Time frame:
During the 2nd PGPS (14 days)
Reported as:
Mean · score on a scale
Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 2nd Peak Grass Pollen Season (PGPS)
score on a scalePlacebo5-grass Mix SLIT-drops
Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 2nd Peak Grass Pollen Season (PGPS)3.64 ± 0.263.09 ± 0.25
Statistical analysis
  • Placebo vs 5-grass Mix SLIT-drops · Mixed Models Analysis · p = 0.1177 (Observed P-value) · Mean difference (final values): 0.55 · 95% CI -0.14 to 1.23Placebo vs 5-grass mix SLIT-drops
SecondaryAverage Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 1st Entire Grass Pollen Season (EGPS)

The average DSS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms (on a scale from 0 to18). Higher scores indicate more severe symptoms. The endpoint is calculated as the average score of all reported daily values during the 1st EGPS.

Time frame:
During the 1st EGPS (observed mean duration of approximately 8 weeks)
Reported as:
Mean · score on a scale
Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 1st Entire Grass Pollen Season (EGPS)
score on a scalePlacebo5-grass Mix SLIT-drops
Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 1st Entire Grass Pollen Season (EGPS)3.82 ± 0.243.61 ± 0.22
Statistical analysis
  • Placebo vs 5-grass Mix SLIT-drops · Mixed Models Analysis · p = 0.4604 (Observed P-value) · Mean difference (final values): 0.21 · 95% CI -0.37 to 0.79Placebo vs 5-grass mix SLIT-drops
SecondaryAverage Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 2nd Entire Grass Pollen Season (EGPS)

The average DSS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms (on a scale from 0 to18). Higher scores indicate more severe symptoms. The endpoint is calculated as the average score of all reported daily values during the 2nd EGPS.

Time frame:
During the 2nd EGPS (observed mean duration of approximately 9 weeks)
Reported as:
Mean · score on a scale
Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 2nd Entire Grass Pollen Season (EGPS)
score on a scalePlacebo5-grass Mix SLIT-drops
Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 2nd Entire Grass Pollen Season (EGPS)3.46 ± 0.232.89 ± 0.22
Statistical analysis
  • Placebo vs 5-grass Mix SLIT-drops · Mixed Models Analysis · p = 0.0549 (Observed P-value.) · Mean difference (final values): 0.57 · 95% CI -0.01 to 1.15Placebo vs 5-grass mix SLIT-drops
SecondaryAverage Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 1st Peak Grass Pollen Season (PGPS)

The average DMS evaluates the treatment effect based on reduction in daily use of rhinoconjunctivitis symptom-relieving medication (on a scale from 0 to 20). Higher scores indicate more medication use. The endpoint is calculated as the average score of all reported daily values during the 1st PGPS.

Time frame:
During the 1st PGPS (14 days)
Reported as:
Mean · units on a scale
Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 1st Peak Grass Pollen Season (PGPS)
units on a scalePlacebo5-grass Mix SLIT-drops
Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 1st Peak Grass Pollen Season (PGPS)3.34 ± 0.342.23 ± 0.25
Statistical analysis
  • Placebo vs 5-grass Mix SLIT-drops · Mixed Models Analysis · p = 0.0049 (Observed P-value.) · Mean difference (final values): 1.12 · 95% CI 0.30 to 1.93Placebo vs 5-grass mix SLIT-drops
SecondaryAverage Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 2nd Peak Grass Pollen Season (PGPS)

The average DMS evaluates the treatment effect based on reduction in daily use of rhinoconjunctivitis symptom-relieving medication (on a scale of 0 to 20). Higher scores indicate more medication use. The endpoint is calculated as the average score of all reported daily values during the 2nd PGPS.

Time frame:
During the 2nd PGPS (14 days)
Reported as:
Mean · score on a scale
Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 2nd Peak Grass Pollen Season (PGPS)
score on a scalePlacebo5-grass Mix SLIT-drops
Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 2nd Peak Grass Pollen Season (PGPS)2.77 ± 0.301.52 ± 0.21
Statistical analysis
  • Placebo vs 5-grass Mix SLIT-drops · Mixed Models Analysis · p = 0.0004 (Observed P-value.) · Mean difference (final values): 1.24 · 95% CI 0.54 to 1.95Placebo vs 5-grass mix SLIT-drops
SecondaryAverage Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 1st Entire Grass Pollen Season (EGPS)

The average DMS evaluates the treatment effect based on reduction in daily use of rhinoconjunctivitis symptom-relieving medication(on a scale from 0 to 20). Higher scores indicate more medication use. The endpoint is calculated as the average score of all reported daily values during the 1st EGPS.

Time frame:
During the 1st EGPS (observed mean duration of approximately 8 weeks)
Reported as:
Mean · score on a scale
Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 1st Entire Grass Pollen Season (EGPS)
score on a scalePlacebo5-grass Mix SLIT-drops
Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 1st Entire Grass Pollen Season (EGPS)3.04 ± 0.352.10 ± 0.27
Statistical analysis
  • Placebo vs 5-grass Mix SLIT-drops · Mixed Models Analysis · p = 0.0054 (Observed P-value.) · Mean difference (final values): 0.94 · 95% CI 0.25 to 1.63Placebo vs 5-grass mix SLIT-drops
SecondaryAverage Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 2nd Entire Grass Pollen Season (EGPS)

The average DMS evaluates the treatment effect based on reduction in daily use of rhinoconjunctivitis symptom-relieving medication (on a scale from 0 to 20). Higher scores indicate more medication use. The endpoint is calculated as the average score of all reported daily values during the 2nd EGPS.

Time frame:
During the 2nd EGPS (observed mean duration of approximately 9 weeks)
Reported as:
Mean · score on a scale
Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 2nd Entire Grass Pollen Season (EGPS)
score on a scalePlacebo5-grass Mix SLIT-drops
Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 2nd Entire Grass Pollen Season (EGPS)2.62 ± 0.311.51 ± 0.23
Statistical analysis
  • Placebo vs 5-grass Mix SLIT-drops · Mixed Models Analysis · p = 0.0002 (Observed P-value.) · Mean difference (final values): 1.11 · 95% CI 0.52 to 1.71Placebo vs 5-grass mix SLIT-drops

Adverse events

Collected over Adverse events (AEs) were collected from consent until the last follow-up phone contact with the participant (approximately 26 months of treatment). The displayed AEs were collected starting on/after time of first IMP administration and no later than 7 days after last IMP administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/223 (0%)6/223 (2.7%)111/223 (49.8%)
5-grass Mix SLIT-drops0/222 (0%)4/222 (1.8%)128/222 (57.7%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlacebo5-grass Mix SLIT-drops
CholelithiasisHepatobiliary disorders1/2231/222
AppendicitisInfections and infestations0/2231/222
Gastrointestinal procedural complicationInjury, poisoning and procedural complications0/2231/222
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2231/222
Ovarian cyst rupturedReproductive system and breast disorders0/2231/222
ChokingRespiratory, thoracic and mediastinal disorders0/2231/222
DiverticulitisInfections and infestations1/2230/222
Lumbar vertebral fractureInjury, poisoning and procedural complications1/2230/222
Wrist fractureInjury, poisoning and procedural complications1/2230/222
Device breakageProduct Issues1/2230/222
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlacebo5-grass Mix SLIT-drops
COVID-19Infections and infestations43/22341/222
NasopharyngitisInfections and infestations43/22338/222
Oral pruritusGastrointestinal disorders11/22340/222
PharyngitisInfections and infestations20/2234/222
HeadacheNervous system disorders19/22311/222
Throat irritationRespiratory, thoracic and mediastinal disorders4/22316/222
Oral discomfortGastrointestinal disorders1/22315/222
Upper respiratory tract infectionInfections and infestations15/22310/222
Viral infectionInfections and infestations7/22314/222
BronchitisInfections and infestations14/2237/222

Baseline characteristics

All randomized and treated participants

Age, Continuous
Age, Continuous(Years)Placebo5-grass Mix SLIT-dropsTotal
Mean33.0 ± 9.732.2 ± 10.132.6 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Placebo5-grass Mix SLIT-dropsTotal
Female10595200
Male118127245
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo5-grass Mix SLIT-dropsTotal
White223222445
Region of Enrollment
Region of Enrollment(participants)Placebo5-grass Mix SLIT-dropsTotal
Czechia5657113
Estonia202
France6713
Latvia171633
Lithuania252651
Poland117116233
Ongoing asthma
Ongoing asthma(Participants)Placebo5-grass Mix SLIT-dropsTotal
Count of participants6359122
08

Study locations

48 sites
  • Fakultni Nemocnice u Sv. Anny - FNUSA
    Brno, 65691, Czechia
  • Alergopraktik s.r.o.
    Jablonec Nad Nisou, 46601, Czechia
  • Allergology Jihlava
    Jihlava, 58601, Czechia
  • Alergologicka Ambulance - Liberec
    Liberec, 46001, Czechia
  • Alergomyšl s.r.o
    Litomyšl, 570 01, Czechia
  • Acredula Benedicta s.r.o.
    Pardubice, 53002, Czechia
  • MUJ ALERGOLOG s.r.o.
    Trutnov, 54101, Czechia
  • KASMED s.r.o.
    Tábor, 39002, Czechia
  • Ambulance alergologie a klinicke imunologie - Ceske Budejovice
    České Budějovice, 37001, Czechia
  • North Estonia Medical Centre Foundation
    Tallinn, 13419, Estonia
  • Hopital Privé de la Loire
    Loiré, Saint-Étienne 42100, France
  • Cabinet medical
    Fenouillet, 31150, France
  • Cabinet medical
    Hyeres, 83400, France
  • Cabinet medical
    Joué-lés-Tours, 37300, France
  • Cabinet medical
    Paris, 75012, France
  • Cabinet médical
    Rezé, 44400, France
  • Cabinet medical
    Saint-Quentin, 02100, France
  • Nouvel Hopital Civil
    Strasbourg, 67091, France
  • CHU Hôpital Larrey
    Toulouse, 31059, France
  • Balvu and Gulbenes hospital union
    Balvi, LV-4501, Latvia
  • Daugavpils Regional hospital, Outpatient clinic
    Daugavpils, LV-5401, Latvia
  • Ozola Inese - Family doctor's practice
    Riga, LV-1003, Latvia
  • The Centre of Investigation and Treatment of Allergic Diseases
    Riga, LV-1003, Latvia
  • Vevere Viktorija - Doctor's Practice in Pneumology and Allergology
    Rēzekne, LV-4601, Latvia
  • M & M Centrs LTD
    Ādaži, LV-2164, Latvia
  • JSC Ausros Medicinos Centras
    Kaunas, 49387, Lithuania
  • Hospital of Lithuanian University of Health Sciences Kauno klinikos
    Kaunas, 50161, Lithuania
  • JSC Inlita, Klaipedos CTC
    Klaipėda, 92231, Lithuania
  • JSC Seimos gydytojas
    Vilnius, 01118, Lithuania
  • JSC Center of Innovative Allergology
    Vilnius, 06256, Lithuania
  • JSC INLITA, Santaros CTC
    Vilnius, 08406, Lithuania
  • Allergy Clinic JSC Perspektyvos
    Vilnius, 08564, Lithuania
  • JSC Center for Diagnosis and Treatment of Allergic Diseases
    Vilnius, LT-08109, Lithuania
  • Grażyna Pulka Centrum Medyczne ALL-MED
    Kraków, Malopolskie 30-033, Poland
  • Alergo-Med Specjalistycza Przychodnia Lekarska Sp. zo.o.
    Tarnów, Maopolskie 33-100, Poland
  • Snzoz Alergologia Plus Ośrodek Diagnostyki i Terapii Uczuleń
    Poznań, Wielkopolskie 60-693, Poland
  • Indywidualna Specjalistyczna Praktyka Lekarska Anna Latos
    Kielce, 25-017, Poland
  • Centrum Usług Medycznych Dyga-Med
    Kraków, 31-033, Poland
  • Grażyna Jasieniak-Pinis ATOPIA NZOZ Poradnie Specjalistyczne
    Kraków, 31-159, Poland
  • Barbara Rewerska Diamond Clinic
    Kraków, 33-559, Poland
  • Specjalistyczna Przychodnia Alergologiczna Centrum Alergologii
    Lublin, 20-552, Poland
  • Centrum Alergologii T.Hofman Sp. Z o.o.
    Poznań, 60-214, Poland
  • Snzoz Imedica
    Poznań, 60-537, Poland
  • Prywatny Gabinet Lekarski Małgorzata Pawlukiewicz
    Rzeszów, 35051, Poland
  • Gabinet Lekarski Bozena Kubicka-Kozik
    Tomaszów Mazowiecki, 97-200, Poland
  • ALL-MED. Specjalistyczna Opieka Medyczna. Medyczny Instytut Badawczy. Marek Jutel.
    Wrocław, 53-201, Poland
  • NZOZ Centrum Usług Medycznych Proximum Sp. z o.o.
    Wrocław, 53-428, Poland
  • Lekarze Specjaliści Malolepszy i Partnerzy
    Wrocław, 54-239, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Sep 2023, 28 months.

Results were first posted in Dec 2024, 1 year 2 months after primary completion.

Of 32 industry-sponsored phase 3 interventional studies under Hypersensitivity, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's 28 months is above that.

Counting every sponsor, half of 42 studies reached it within 23 months; a quarter within 10 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2021
First posted
May 11, 2021
StartActual
May 10, 2021
Primary completionActual
Sep 26, 2023
CompletionActual
Sep 26, 2023
Results first posted
Dec 16, 2024
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04881461
Lead sponsor
ALK-Abelló A/S
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
May 11, 2021
Start date
May 10, 2021
Primary completion
Sep 26, 2023
Completion
Sep 26, 2023
Results posted
Dec 16, 2024
Last update
Dec 16, 2024

Study contacts

Laurent Guilleminault, MD
principal investigator · CHU Hôpital Larrey

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion